The IACT project (FP7) website is up and running

07-09-2015

LeadArtis is a partner of the IACT (Immunostimulatory Agonist Antibodies for Cancer Therapy) 6.9M€ funding consortium (Project Number: 602262). The IACT is an interdisciplinary platform that involves a total of 10 partners with long-standing expertise in agonist immunostimulatory antibodies (IS-Abs), from research institutions and small-medium enterprises (SEM) located in five European countries (Germany, Italy, Spain, Sweden and United Kingdom). Recently the website regarding this project (http://www.iact-project.eu/has been elaborated and is now ready for its visualization. We find the information included in the site relevant and a good basis to start interacting with other immunotherapy-oriented EU-projects, companies and research groups.

The IACT program aims to translate the agonist IS-Ab concept into clinical treatments. Two ongoing clinical trials are pivotal to bring forward the pre-clinical Proof of Concept in which striking therapeutic impact with agonist IS-Abs has been obtained. A parallel SME-driven effort will aim at the development of 2nd generation agonist IS-Abs with superior therapeutic index. In this regard, LeadArtis will apply its TrimerbodyTM technology to the development of optimized agonist IS-Abs and for strengthening the IACT agonist IS-Ab pipeline.

Latest News

LeadArtis to present at the final Chemostart pitching initiative in recognition of its highly innovative R&D activity
31-01-2019
The Chemostart initiative (sponsored by the Chemo company) launched in 2018 as a call for...
LeadArtis project finalist of the Kaertor and J&J innovation award in recognition of its highly innovative R&D activity
08-11-2018
The Kærtor Foundation together with Janssen (a Johnson & Johnson company) launched in 2018...
Leadartis discloses the project: ATTACK-Cancer immunotherapy by bispecific antibodies that recruit T lymphocytes
11-12-2018

LeadArtis is pleased to announce its participation as coordinator of the ATTACK project (Cancer...